- Home
- CHRS vs ALTG Comparison
CHRS vs ALTG Comparison
Compare CHRS & ALTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ALTG
- Stock Information
- Founded
- CHRS 2010
- ALTG 1984
- Country
- CHRS United States
- ALTG United States
- Employees
- CHRS N/A
- ALTG N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ALTG Industrial Machinery/Components
- Sector
- CHRS Health Care
- ALTG Industrials
- Exchange
- CHRS Nasdaq
- ALTG Nasdaq
- Market Cap
- CHRS 112.5M
- ALTG 119.3M
- IPO Year
- CHRS 2014
- ALTG N/A
- Fundamental
- Price
- CHRS $0.78
- ALTG $4.75
- Analyst Decision
- CHRS Buy
- ALTG Buy
- Analyst Count
- CHRS 3
- ALTG 3
- Target Price
- CHRS $4.68
- ALTG $11.67
- AVG Volume (30 Days)
- CHRS 1.5M
- ALTG 162.3K
- Earning Date
- CHRS 05-12-2025
- ALTG 05-07-2025
- Dividend Yield
- CHRS N/A
- ALTG 4.80%
- EPS Growth
- CHRS N/A
- ALTG N/A
- EPS
- CHRS N/A
- ALTG N/A
- Revenue
- CHRS $272,251,000.00
- ALTG $1,858,000,000.00
- Revenue This Year
- CHRS N/A
- ALTG $2.05
- Revenue Next Year
- CHRS $19.78
- ALTG $3.24
- P/E Ratio
- CHRS $1.83
- ALTG N/A
- Revenue Growth
- CHRS 19.87
- ALTG N/A
- 52 Week Low
- CHRS $0.66
- ALTG $3.54
- 52 Week High
- CHRS $2.43
- ALTG $11.39
- Technical
- Relative Strength Index (RSI)
- CHRS 40.90
- ALTG 47.44
- Support Level
- CHRS $0.74
- ALTG $4.74
- Resistance Level
- CHRS $0.82
- ALTG $5.12
- Average True Range (ATR)
- CHRS 0.07
- ALTG 0.27
- MACD
- CHRS -0.00
- ALTG -0.04
- Stochastic Oscillator
- CHRS 19.71
- ALTG 2.15
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About ALTG Alta Equipment Group Inc.
Alta Equipment Group Inc is an integrated equipment dealership platform in the U.S. Its segments are Material Handling and Construction Equipment. The Material Handling segment is engaged in operations related to the sale, service, and rental of lift trucks in Michigan, Illinois, Indiana, New York, Virginia, and throughout the New England states whereas, the Construction Equipment segment is principally engaged in operations related to the sale, service, and rental of construction equipment in Michigan, Indiana, Illinois, Ohio, New York, Florida and throughout the New England States.